Pre-op assessment should consider interactions between demographic and ocular factors

Article

Corneal refractive surgery may be more successful in eyes in which the cylinder mainly originates from the anterior cornea; therefore, in candidates for refractive surgery, surgeons should carefully assess the interaction between topographic, refractive and ocular residual astigmatism (ORA) to identify those at high risk for having significant differences between subjective cylinder and topographic astigmatism.

Corneal refractive surgery may be more successful in eyes in which the cylinder mainly originates from the anterior cornea; therefore, in candidates for refractive surgery, surgeons should carefully assess the interaction between topographic, refractive and ocular residual astigmatism (ORA) to identify those at high risk for having significant differences between subjective cylinder and topographic astigmatism. These conclusions were made by the authors of a study recently published in the Journal of Cataract & Refractive Surgery.

Researchers included 2991 eyes from 2991 myopic patients scheduled for LASIK to evaluate the influence of age, sex, ocular dominance, subjective cylinder and topographic astigmatism, subjective sphere and myopic pupil size on preexisting ocular residual astigmatism. A total of 46% of eyes had an ORA of 1.00 D or more.

Using ordinary least square estimations and odds ratios, researchers determined that negative predictors of the degree of preoperative ORA included subjective sphere, male sex and dominant eye, and that increasing age and larger mesopic pupils did not indicate ORA orientation. Further, with-the-rule astigmatism meridian was more likely to occur in eyes with low ORA, and oblique and against-the-rule meridians were related to high ORA.

To access this study, click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.